Baltimore's Profectus marks key step in race for Ebola vaccine

April 9, 2015 5:46 AM

17 0

An Ebola vaccine being developed by Baltimore company Profectus BioSciences is effective against the strain of the virus that has ravaged West Africa, research to be published Thursday suggests — a milestone the company says is a first in the race to prevent outbreaks of the deadly disease.

While other leading vaccine candidates have progressed to human trials in Africa, published data on the protection they provide is based on tests exposing animals to a relatively mild laboratory version of the Ebola virus, or strains from previous outbreaks.

Read more

To category page